These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27367295)

  • 1. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
    Gane EJ; Hyland RH; An D; Svarovskaia ES; Brainard D; McHutchison JG
    Antivir Ther; 2016; 21(7):605-609. PubMed ID: 27367295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
    Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
    HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
    Deterding K; Spinner CD; Schott E; Welzel TM; Gerken G; Klinker H; Spengler U; Wiegand J; Schulze Zur Wiesch J; Pathil A; Cornberg M; Umgelter A; Zöllner C; Zeuzem S; Papkalla A; Weber K; Hardtke S; von der Leyen H; Koch A; von Witzendorff D; Manns MP; Wedemeyer H;
    Lancet Infect Dis; 2017 Feb; 17(2):215-222. PubMed ID: 28029529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
    BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
    Lawitz E; Poordad F; Hyland RH; Wang J; Liu L; Dvory-Sobol H; Brainard DM; McHutchison JG; Gutierrez JA
    Antivir Ther; 2016; 21(8):679-687. PubMed ID: 27348483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
    Jensen CM; Holle LM
    Pharmacotherapy; 2016 May; 36(5):562-74. PubMed ID: 27027412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
    Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
    Singh T; Guirguis J; Anthony S; Rivas J; Hanouneh IA; Alkhouri N
    Liver Int; 2016 Jun; 36(6):802-6. PubMed ID: 26824848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
    Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
    Liu CJ; Sheen IS; Chen CY; Chuang WL; Wang HY; Tseng KC; Chang TT; Yang J; Massetto B; Suri V; Camus G; Jiang D; Zhang F; Gaggar A; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Clin Infect Dis; 2022 Aug; 75(3):453-459. PubMed ID: 34864948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Ahmed H; Elgebaly A; Abushouk AI; Hammad AM; Attia A; Negida A
    Antivir Ther; 2017; 22(5):369-379. PubMed ID: 27588749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A
    J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.